Condition

Stage IIIB Breast Cancer AJCC v7

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 34 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials34

Recruiting0

Common interventions25

Lead sponsors shown9

Clinical trials

34 shown

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryNCT04197687 · 2020-02-20

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyNCT03872388 · 2019-09-23

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy AdherenceNCT04054557 · 2019-07-31

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast CancerNCT03411070 · 2019-04-07

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer SurvivorsNCT03407716 · 2019-03-01

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryNCT03317405 · 2018-10-31

ACTIVE_NOT_RECRUITING

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityNCT03428802 · 2018-03-08

ACTIVE_NOT_RECRUITING

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerNCT03101748 · 2018-02-19

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyNCT03281902 · 2017-11-13

ACTIVE_NOT_RECRUITING

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerNCT03106415 · 2017-09-27

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing SurgeryNCT03038152 · 2017-04-11

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerNCT03012100 · 2017-03-31

ACTIVE_NOT_RECRUITING

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCNCT02593175 · 2016-11-03

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerNCT02689427 · 2016-09-22

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer TreatmentNCT02754752 · 2016-09-13

ACTIVE_NOT_RECRUITING

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31

ACTIVE_NOT_RECRUITING

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerNCT02474173 · 2016-01-15

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeNCT02276443 · 2015-11-09

ACTIVE_NOT_RECRUITING

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerNCT02311933 · 2015-05-28

ACTIVE_NOT_RECRUITING

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsNCT02152943 · 2014-07-17

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18

The Role of Lifestyle Factors in Breast Cancer-Related OutcomesNCT02079662 · 2013-06-13

ACTIVE_NOT_RECRUITING

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNCT01552434 · 2012-10-16

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast CancerNCT01463072 · 2012-06-19

ACTIVE_NOT_RECRUITING

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT01351909 · 2011-05-02

ACTIVE_NOT_RECRUITING

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerNCT01251874 · 2010-11-22

ACTIVE_NOT_RECRUITING

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerNCT01142401 · 2010-05-26

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryNCT00770809 · 2009-02-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerNCT00684983 · 2008-07-30

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveNCT00390455 · 2006-09-15

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT00376688 · 2006-07-11

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)NCT00310180 · 2006-04-07

ACTIVE_NOT_RECRUITING

Common interventions

Leading sponsors

National Cancer Institute (NCI) 14 M.D. Anderson Cancer Center 10 Mayo Clinic 3 Academic and Community Cancer Research United 2 City of Hope Medical Center 1 Jonsson Comprehensive Cancer Center 1 Rutgers, The State University of New Jersey 1 Thomas Jefferson University 1 University of California, San Francisco 1

Trial status mix

COMPLETED16

ACTIVE_NOT_RECRUITING13

TERMINATED4

UNKNOWN1

Phase mix

PHASE216

PHASE19

PHASE34

NA3

EARLY_PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.